Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexamethasone controlled-release implant - EyePoint Pharmaceuticals

Next Previous
Drug Profile

Dexamethasone controlled-release implant - EyePoint Pharmaceuticals

Alternative Names: Dexamethasone sustained-release - EyePoint Pharmaceuticals

Latest Information Update: 14 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator pSivida
  • Developer EyePoint Pharmaceuticals; Hospital for Special Surgery
  • Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Osteoarthritis

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Osteoarthritis in USA (Implant)
  • 28 Mar 2018 pSivida is now called EyePoint Pharmaceuticals
  • 14 Dec 2017 Efficacy and adverse events data from a phase I trial in Osteoarthritis released by pSivida

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top